Insider Trading & Ownership of Matthew K. Fust

Location: Novato, CA
Summary: The estimated net worth of Matthew K. Fust is at least $2.49M dollars as of 30 Sep 2025. Matthew K. Fust is the Director of Crinetics Pharmaceuticals, Inc. and owns shares of Crinetics Pharmaceuticals, Inc. (CRNX) stock worth about $1.02M. Matthew K. Fust is the Director of Ultragenyx Pharmaceutical Inc. and owns shares of Ultragenyx Pharmaceutical Inc. (RARE) stock worth about $985K. Matthew K. Fust is the Director of Neumora Therapeutics, Inc. and owns shares of Neumora Therapeutics, Inc. (NMRA) stock worth about $342K. Matthew K. Fust is the Director of Atara Biotherapeutics, Inc. and owns shares of Atara Biotherapeutics, Inc. (ATRA) stock worth about $138K.
Signature: /s/ Tobin Schilke, as attorney-in-fact
All Insider Reports: All Insider Reports

Notify me when Matthew K. Fust files a new Insider Trading report.

Ownership of Matthew K. Fust

Symbol	Company	Relationship	Holdings Value	Past Year Net Change	Change %	Report Period
CRNX	Crinetics Pharmaceuticals, Inc.	Director	$1.02M	-$716K	-41.2%	26 Sep 2025
RARE	Ultragenyx Pharmaceutical Inc.	Director	$985K			15 May 2025
NMRA	Neumora Therapeutics, Inc.	Director	$342K			28 May 2025
ATRA	Atara Biotherapeutics, Inc.	Director	$138K			10 Jun 2025

Sym	Company	Class	Transaction	%	Value $	* Price $	Shares	Shares After	Date	Ownership

* An asterisk sign (*) next to the price indicates that the price is likely invalid.